INYANDIKO Z'UBU
CAR-T yo kurwanya Glioblastoma
Glioblastoma ni imwe mu ndwara zikunze kugaragara kandi zigoye mu bwonko ku bantu bakuru. Ikomoka ku turemangingo tw’ubwonko mu bwonko kandi izwiho gukura vuba no kwinjira mu ngingo zikikije, bigatuma kuyikuraho burundu bigorana. Ibimenyetso bishobora kuba birimo kuribwa umutwe, gucika intege, impinduka mu mitekerereze, no kubura ubushobozi bwo mu bwonko, bitewe n’aho ikibyimba giherereye. Nubwo ubuvuzi busanzwe bushobora gufasha mu guhangana n’iyi ndwara, abarwayi benshi bashaka uburyo bwo kuvura kugira ngo barusheho kunoza umusaruro n’imibereho myiza.
Uburyo bwo kuvura kanseri y'igifu bwa CAR-T
Uburyo bwo kuvura kanseri y'igifu bwa CAR-T ni uburyo bugezweho bwo kuvura indwara ziterwa n'umubiri, burimo gukoreshwa cyane mu kuvura kanseri y'igifu. BIOOCUS yateguye ibikoresho bya CAR-T byibanda ku miti irwanya kanseri y'igifu nka Claudin18.2 na HER2, bigaragaza ko bigira ingaruka nziza ku barwayi bananiwe ubuvuzi bwinshi mbere—urugero, CT041 yageze ku kigero cya 57.1%, DCR ya 75%, n'umubare w'amezi 6 wo kubaho wa 81.2%. Ikoresheje urubuga mpuzamahanga rwa GMP, itsinda ry'impuguke mu nzego zitandukanye, n'uburambe bwinshi ku isi, BIOOCUS itanga igisubizo cyuzuye, cyiza kandi cyuzuye cyo kuvura kanseri y'igifu cya CAR-T ku barwayi.
CAR-T yo kuvura indwara ya Systemic Lupus Erythematosus (SLE)
Uburyo bwo kuvura uturemangingo twa CAR-T (Chimeric Antigen Receptor T) ni uburyo bwo kuvura ubudahangarwa bw’umubiri bwagaragaje ubushobozi bwo kuvura SLE hifashishijwe urwego rw’uturemangingo twa B, bigira uruhare runini mu gutera indwara. Muri SLE, uturemangingo twa B dukora uturemangingo twibasira ingirabuzimafatizo z’umubiri, bigatera ububyimbirwe budakira no kwangirika kw’ingingo. Uburyo bwo kuvura bwa CAR-T bukora hifashishijwe uturemangingo twa T kugira ngo dukore receptor (CAR) yibasira by’umwihariko CD19, ikimenyetso ku turemangingo twa B, bigatera kwangirika kw’utu turemangingo twa B twangiza.
Uturemangingo twa CAR-T twibasira uturemangingo twa CD19+ B dutanga uburyo bwiza kandi burambye bwo kugabanya uturemangingo twa B ugereranije n'ubundi buryo bwo kuvura, burwanya CD20 ariko ntibushobore gukuraho uturemangingo twa plasma tumara igihe kirekire. Uku kugabanuka gukomeye kw'uturemangingo twa B bishobora gutuma ibimenyetso bya SLE bigabanuka binyuze mu gukuraho uturemangingo dushinzwe gukora uturemangingo twa autoantibody. Ubushakashatsi kandi bunasesengura CAR-Treg (uturemangingo twa CAR-T twagenewe kugenzura uburyo ubudahangarwa bw'umubiri bukora) kugira ngo twongere ubushobozi bwo kwihanganira ubudahangarwa bw'umubiri no kugabanya imikorere y'uturemangingo tw'umubiri.
FUCASO: Ubuvuzi bwa BCMA CAR-T bugezweho bufite imikorere n'umutekano bidasanzwe
FUCASO ni uburyo bushya bwo kuvura CAR-T bushingiye kuri BCMA bukorwa na IASO BIO, butanga imikorere myiza n'umutekano ku ndwara ya myeloma nyinshi yasubiwemo cyangwa idashobora kuvura. Hamwe n'uburyo bwo gusubiza indwara ku buryo buhanitse, kugabanuka ku buryo burambye, no kugira umutekano ukomeye, FUCASO itanga icyizere gishya ku barwayi kandi ishyiraho amahame mashya mu kuvura CAR-T.
Incamake yuzuye y'ubuvuzi buteye ubwoba bwa kanseri y'amaraso
Ubuvuzi bwa CAR-T, mu magambo ahinnye asobanura Chimeric Antigen Receptor T-Cell Immunotherapy, ni uburyo bugezweho bwo kuvura imiterere y’uturemangingo bukoresha uburyo bwo guhindura uturemangingo twa T tw’umurwayi kugira ngo twibasire kandi tumene uturemangingo twa kanseri. Bitandukanye n’imiti gakondo, ubuvuzi bwa CAR-T bugenewe buri murwayi kandi busaba gukusanya uturemangingo twa T mu maraso y’umurwayi mbere yo kongera kutwongerera mu mubiri nyuma yo gukora inyigo y’imiterere y’uturemangingo.